Fundz
Following Tessera Therapeutics?

Get the free weekly product launch digest

The latest product launches, like Tessera Therapeutics’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New product launches, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Launch Trends

See who's moving and how much in your market

No credit card required Weekly product launch digest

Tessera Therapeutics Showcases Innovative Gene Writing Data at ESGCT Congress in Rome

Oct 24, 2024•over 1 year ago
Somerville

Product Description

Tessera Therapeutics presents new preclinical data on its Gene Writing™ technology for treating AATD and SCD at the European Society of Gene and Cell Therapy Congress. The company demonstrates significant advances in rewriting efficiencies and safety evaluation methods for its genetic medicine programs.

Company Information

Company

Tessera Therapeutics

Location

Somerville, Pennsylvania, United States

About

Tessera Therapeutics is pioneering GENE WRITING technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. The GENE WRITING platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo. Tessera Therapeutics was founded by Flagship Pioneering in 2018, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability. For more information about Tessera, please visit www.tesseratherapeutics.com.

Predictive Intelligence
Strategic

ML-powered predictions for Tessera Therapeutics's next move

Learn about Strategic plan

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.